Moreover, the recent realization that acute lung injury induces the release of CGRP, which in turn is implicated in COVID-19 symptoms, such as cough, fever, pain, and the release of IL-6, might illuminate a new scenario in which “gepants” might be used to target the SARS-CoV-2 nsp16/nsp10 complex while treating excessive lung inflammation caused by SARS-CoV-2. This evidence concerns the gene IL6 and COVID-19.